MicroRNAs in renal cell carcinoma: A systematic review of clinical implications (Review)

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1571-1578

  Li, Ming ^a,b   Wang, Ying ^a   Song, Yongsheng ^a   Bu, Renge ^a   Yin, Bo ^a   Fei, Xiang ^a   Guo, Qizhen ^a   Wu, Bin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diagnosis; MicroRNA; Prognosis; Renal cell carcinoma; Therapy

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MICRORNA 1 133A; MICRORNA 133B; MICRORNA 135A; MICRORNA 141; MICRORNA 141 145; MICRORNA 145; MICRORNA 155; MICRORNA 182 5P; MICRORNA 187; MICRORNA 200C; MICRORNA 21; MICRORNA 210; MICRORNA 217; MICRORNA 218; MICRORNA 224 383; MICRORNA 23B; MICRORNA 23B 3P; MICRORNA 30C; MICRORNA 30D; MICRORNA 34A; MICRORNA 381; MICRORNA 590 5P; MICRORNA 7; MICRORNA 708; MICRORNA 99A; MOLECULAR MARKER; UNCLASSIFIED DRUG; ADENYLATE KINASE; ADENYLATE KINASE 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; TUMOR MARKER; TUMOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CARCINOGENESIS; DRUG TARGETING; EARLY DIAGNOSIS; GENE FUNCTION; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; BLOOD; CARCINOMA, RENAL CELL; CHROMOSOMAL INSTABILITY; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

ADENYLATE KINASE; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CHROMOSOMAL INSTABILITY; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84924860402     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3799     Document Type: Review

References (106)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
3. Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol 20: 300-306, 2008.
4. Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843-852, 2003.
5. Bullock A, McDermott DF and Atkins MB: Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Manag Res 2: 123-132, 2010.
6. Lilleby W and Fossa SD: Chemotherapy in metastatic renal cell cancer. World J Urol 23: 175-179, 2005.
7. Redova M, Svoboda M and Slaby O: MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun 405: 153-156, 2011.
8. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
9. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
10. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
11. Rodriguez A, Griffiths-Jones S, Ashurst JL and Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res 14: 1902-1910, 2004.
12. Saini HK, Griffiths-Jones S and Enright AJ: Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 104: 17719-17724, 2007.
13. Cai X, Hagedorn CH and Cullen BR: Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10: 1957-1966, 2004.
14. Lee Y, Kim M, Han J, et al: MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060, 2004.
15. Denli AM, Tops BB, Plasterk RH, Ketting RF and Hannon GJ: Processing of primary microRNAs by the microprocessor complex. Nature 432: 231-235, 2004.
16. Han J, Lee Y, Yeom KH, Kim YK, Jin H and Kim VN: The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18: 3016-3027, 2004.
17. Lund E, Guttinger S, Calado A, Dahlberg JE and Kutay U: Nuclear export of microRNA precursors. Science 303: 95-98, 2004.
18. Yi R, Qin Y, Macara IG and Cullen BR: Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17: 3011-3016, 2003.
19. Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12, 2007.
20. Jackson RJ and Standart N: How do microRNAs regulate gene expression? Sci STKE: Jan 2, 2007 (Epub ahead of print). doi: 10.1126/stke.3672007re1.
21. Nilsen TW: Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 23: 243-249, 2007.
22. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126, 2007.
23. Kawakami K, Enokida H, Chiyomaru T, et al: The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 48: 827-836, 2012.
24. Huang J, Yao X, Zhang J, et al: Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. Cancer Sci 104: 1609-1617, 2013.
25. Yu H, Lin X, Wang F, et al: Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells. Oncol Lett 7: 799-804, 2014.
26. Yamamura S, Saini S, Majid S, et al: MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 33: 294-300, 2012.
27. Zhang C, Mo R, Yin B, Zhou L, Liu Y and Fan J: Tumor suppressor microRNA-34a inhibits cell proliferation by targeting Notch1 in renal cell carcinoma. Oncol Lett 7: 1689-1694, 2014.
28. Cui L, Zhou H, Zhao H, et al: MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 12: 546, 2012.
29. Wu D, Pan H, Zhou Y, Zhou J, Fan Y and Qu P: microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep 9: 2491-2498, 2014.
30. Yamada Y, Hidaka H, Seki N, et al: Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci 104: 304-312, 2013.
31. Yamasaki T, Seki N, Yamada Y, et al: Tumor suppressive microRNA138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol 41: 805-817, 2012.
32. Song T, Zhang X, Wang C, et al: MiR-138 suppresses expression of hypoxia-inducible factor 1? (HIF-1?) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev 12: 1307-1311, 2011.
33. Liang J, Zhang Y, Jiang G, et al: MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res 21: 83-91, 2013.
34. Yu XY, Zhang Z, Liu J, Zhan B and Kong CZ: MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B. Onco Targets Ther 6: 349-354, 2013.
35. Chen X, Wang X, Ruan A, et al: miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 20: 2617-2630, 2014.
36. Yoshino H, Enokida H, Itesako T, et al: Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci 104: 1567-1574, 2013.
37. Doberstein K, Steinmeyer N, Hartmetz AK, et al: MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 15: 218-230, 2013.
38. Lu R, Ji Z, Li X, et al: miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol 140: 387-397, 2014.
39. Xu X, Wu J, Li S, et al: Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway. Mol Cancer 13: 109, 2014.
40. Zhao J, Lei T, Xu C, et al: MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. Biochem Biophys Res Commun 438: 439-444, 2013.
41. Khella HW, Bakhet M, Allo G, et al: miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34: 2231-2239, 2013.
42. Huang J, Dong B, Zhang J, et al: miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol 35: 5833-5843, 2014.
43. Wang X, Chen X, Wang R, et al: microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis. Oncol Rep 30: 643-650, 2013.
44. Majid S, Saini S, Dar AA, et al: MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res 71: 2611-2621, 2011.
45. Li H, Zhao J, Zhang JW, et al: MicroRNA-217, down-regulated in clear cell renal cell carcinoma and associated with lower survival, suppresses cell proliferation and migration. Neoplasma 60: 511-515, 2013.
46. Yamasaki T, Seki N, Yoshino H, et al: MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol 190: 1059-1068, 2013.
47. Zhai Q, Zhou L, Zhao C, et al: Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun 419: 621-626, 2012.
48. Zhang WB, Pan ZQ, Yang QS and Zheng XM: Tumor suppressive miR-509-5p contributes to cell migration, proliferation and antiapoptosis in renal cell carcinoma. Ir J Med Sci 182: 621-627, 2013.
49. Ueno K, Hirata H, Shahryari V, et al: Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br J Cancer 104: 308-315, 2011.
50. Saini S, Yamamura S, Majid S, et al: MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 71: 6208-6219, 2011.
51. Hidaka H, Seki N, Yoshino H, et al: Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3: 44-57, 2012.
52. Yamasaki T, Seki N, Yoshino H, et al: Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma. Cancer Sci 104: 1411-1419, 2013.
53. Hirata H, Hinoda Y, Ueno K, Nakajima K, Ishii N and Dahiya R: MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis 33: 501-508, 2012.
54. Yu Z, Ni L, Chen D, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol 44: 669-677, 2013.
55. Li X, Xin S, He Z, et al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 33: 1631-1642, 2014.
56. Lv L, Huang F, Mao H, et al: MicroRNA-21 is overexpressed in renal cell carcinoma. Int J Biol Markers 28: 201-207, 2013.
57. Dey N, Das F, Ghosh-Choudhury N, et al: microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One 7: e37366, 2012.
58. Zhang A, Liu Y, Shen Y, Xu Y and Li X: miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. Urology 78: e13-e19, 2011.
59. Zaman MS, Thamminana S, Shahryari V, et al: Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One 7: e50203, 2012.
60. Liu W, Zabirnyk O, Wang H, et al: miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene 29: 4914-4924, 2010.
61. Li S, Chen T, Zhong Z, Wang Y, Li Y and Zhao X: microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep 5: 949-954, 2012.
62. Nakada C, Tsukamoto Y, Matsuura K, et al: Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol 224: 280-288, 2011.
63. Boguslawska J, Wojcicka A, Piekielko-Witkowska A, Master A and Nauman A: MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS One 6: e24541, 2011.
64. Xiao X, Tang C, Xiao S, Fu C and Yu P: Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells. Oncol Res 20: 537-544, 2013.
65. Jung M, Mollenkopf HJ, Grimm C, et al: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13: 3918-3928, 2009.
66. Gottardo F, Liu CG, Ferracin M, et al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25: 387-392, 2007.
67. Cheng T, Wang L, Li Y, Huang C, Zeng L and Yang J: Differential microRNA expression in renal cell carcinoma. Oncol Lett 6: 769-776, 2013.
68. Faragalla H, Youssef YM, Scorilas A, et al: The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 14: 385-392, 2012.
69. Silva-Santos RM, Costa-Pinheiro P, Luis A, et al: MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 109: 2646-2653, 2013.
70. Wotschofsky Z, Liep J, Meyer HA, et al: Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci 8: 1363-1374, 2012.
71. Heinzelmann J, Henning B, Sanjmyatav J, et al: Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29: 367-373, 2011.
72. Redova M, Poprach A, Nekvindova J, et al: Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10: 55, 2012.
73. Teixeira AL, Ferreira M, Silva J, et al: Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35: 4057-4066, 2014.
74. Lichner Z, Mejia-Guerrero S, Ignacak M, et al: Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxiarelated signaling pathways. Am J Pathol 180: 1675-1687, 2012.
75. Neal CS, Michael MZ, Rawlings LH, Van Der Hoek MB and Gleadle JM: The VHL-dependent regulation of microRNAs in renal cancer. BMC Med 8: 64, 2010.
76. Lian JH, Wang WH, Wang JQ, Zhang YH and Li Y: MicroRNA-122 promotes proliferation, invasion and migration of renal cell carcinoma cells through the PI3K/Akt signaling pathway. Asian Pac J Cancer Prev 14: 5017-5021, 2013.
77. Bera A, Ghosh-Choudhury N, Dey N, et al: NFkappaB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. Cell Signal 25: 2575-2586, 2013.
78. Bera A, Das F, Ghosh-Choudhury N, Kasinath BS, Abboud HE and Choudhury GG: microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKbeta-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res 328: 99-117, 2014.
79. Hildebrandt MA, Gu J, Lin J, et al: Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29: 5724-5728, 2010.
80. Gebauer K, Peters I, Dubrowinskaja N, et al: Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer 108: 131-138, 2013.
81. Beresneva EV, Rykov SV, Hodyrev DS, et al: Methylation profile of group of miRNA genes in clear cell renal cell carcinoma; involvement in cancer progression. Genetika 49: 366-375, 2013.
82. Creighton CJ, Morgan M, Gunaratne PH, et al: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49, 2013.
83. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG and Wu X: Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31: 1805-1812, 2010.
84. Hell MP, Thoma CR, Fankhauser N, Christinat Y, Weber TC and Krek W: miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. Cancer Res 74: 2432-2443, 2014.
85. Prior C, Perez-Gracia JL, Garcia-Donas J, et al: Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 9: e86263, 2014.
86. Powers MP, Alvarez K, Kim HJ and Monzon FA: Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Diagn Mol Pathol 20: 63-70, 2011.
87. Zaravinos A, Lambrou GI, Mourmouras N, et al: New miRNA profiles accurately distinguish renal cell carcinomas and upper tract urothelial carcinomas from the normal kidney. PLoS One 9: e91646, 2014.
88. Youssef YM, White NM, Grigull J, et al: Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59: 721-730, 2011.
89. Wulfken LM, Moritz R, Ohlmann C, et al: MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6: e25787, 2011.
90. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F and Takenaka A: Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol 44: 53-58, 2014.
91. Zhao A, Li G, Peoc'h M, Genin C and Gigante M: Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 94: 115-120, 2013.
92. Von Brandenstein M, Pandarakalam JJ, Kroon L, et al: MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 180: 1787-1797, 2012.
93. Gao Y, Zhao H, Lu Y, Li H and Yan G: MicroRNAs as potential diagnostic biomarkers in renal cell carcinoma. Tumour Biol: Aug 6, 2014 (Epub ahead of print). doi: 10.1007/s13277-014-2381-3.
94. Shinmei S, Sakamoto N, Goto K, et al: MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Int J Urol 20: 468-477, 2013.
95. Slaby O, Redova M, Poprach A, et al: Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 51: 707-716, 2012.
96. Wang G, Chen L, Meng J, Chen M, Zhuang L and Zhang L: Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol 45: 373-379, 2013.
97. Zhao JJ, Chen PJ, Duan RQ, Li KJ, Wang YZ and Li Y: Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 7: 3318-3323, 2014.
98. Wu X, Weng L, Li X, et al: Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7: e35661, 2012.
99. Slaby O, Jancovicova J, Lakomy R, et al: Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29: 90, 2010.
100. Berkers J, Govaere O, Wolter P, et al: A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelialto-mesenchymal transition and hypoxia resistance. J Urol 189: 1930-1938, 2013.
101. Chen B, Duan L, Yin G, Tan J and Jiang X: Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells-Cdc2 activity is up-regulated by targeting WEE1. Clinics 68: 825-833, 2013.
102. Yu G, Li H, Wang J, et al: miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. J Urol: May 24, 2014 (Epub ahead of print). doi: 10.1016/j.juro.2014.05.094.
103. Redova M, Poprach A, Besse A, et al: MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol 34: 481-491, 2013.
104. Schiffgen M, Schmidt DH, von Rucker A, Muller SC and Ellinger J: Epigenetic regulation of microRNA expression in renal cell carcinoma. Biochem Biophys Res Commun 436: 79-84, 2013.
105. Chen B, Duan L, Yin G, Tan J and Jiang X: miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J Chemother 25: 229-238, 2013.
106. Wang J, He J, Su F, et al: Repression of ATR pathway by miR-185 enhances radiation-induced apoptosis and proliferation inhibition. Cell Death Dis 4: e699, 2013.